Continued Emergence of Targeted Therapies for EGFR-Mutant NSCLC Underscores Importance of Molecular Testing
Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.
Source: onclive.com